News from NORD

Neuroendocrine Tumor Research Foundation Posts RFPs for $1.2 Million in Grants

Publish date: September 1, 2016

“Accelerator Grants” to advance research to cure neuroendocrine cancers have just been announced by the Neuroendocrine Tumor Research Foundation. With these grants, NETRF is launching the most ambitious privately funded global research effort ever undertaken to control and cure neuroendocrine cancers.

NETRF is seeking proposals for significant NET research projects with each grant award of up to $1.2 million over four years. “NETRF seeks to fund the most dedicated teams and robust proposals to transform the landscape of NET research,” said Lauren Erb, Director of Research.

The Accelerator Grants program was established by automobile publishing giant Robert Petersen, who passed away from neuroendocrine cancer in 2007. Competitive proposals are being sought in this international program and all proposals will be evaluated in a rigorous review process by the NETRF Board of Scientific Advisors.

 

Recommended Reading

Edaravone slows progression of ALS when started early on
MDedge Neurology
Heat shock protein peptide vaccine appears safe, effective for glioblastoma patients
MDedge Neurology
Updated Behçet’s disease recommendations expand biologic treatment
MDedge Neurology
Intermediate alleles may confer mild, late-onset Huntington-like symptoms
MDedge Neurology
Hemophilia drugs top Medicaid spending per prescription
MDedge Neurology
NORD Rare Diseases and Orphan Products Summit to Feature Speakers from FDA, NIH, and ACMG
MDedge Neurology
NORD Issues Statement as US Senate Postpones Vote on Cures Legislation
MDedge Neurology
Myth of the Month: Vaccinations in patients with Guillain-Barré syndrome
MDedge Neurology
Can Coenzyme Q10 Supplementation Benefit Patients With MSA?
MDedge Neurology
Research Training Fellowship in Ataxia is Available
MDedge Neurology